![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Orexo announces termination of OX-CLI and OX-ESI programs
Orexo and Janssen Pharmaceuticals, formerly Ortho-McNeil-Janssen Pharmaceuticals, and Janssen Pharmaceutica, have terminated their research...
Precision receives US patent related to engineered meganucleases
Precision BioSciences has received US patent which covers claims related to methods of cleaving...
Vanda reports positive data of tasimelteon in Non-24-Hour Disorder
Vanda Pharmaceuticals' tasimelteon has shown the ability to reset the body clock and to...
Prosensa secures financing to develop RNA-modulating therapeutics
Dutch-based biopharmaceutical company, Prosensa has raised €23m in new equity financing to advance its...
Selventa receives new patent for discovery of biomarker profiles
Selventa, a biomarker discovery company, has received US patent entitled Computer-aided Discovery of Biomarker Profiles...
Upsher-Smith launches new prenatal vitamin
Upsher-Smith Laboratories has launched B-Nexa, a prescription prenatal vitamin for pregnant women who suffer...
Merck will pay a maximum of $37 million to settle all claims against its...
The settlement includes $10 million in costs and fees, and will total between $21.8...
BTG receives US Voraxaze approval
UK-based pharmaceutical company BTG has received US Food and Drug Adminsitration (FDA) approval for its Voraxaze...
AstraZeneca and Bristol-Myers Squibb diabetes drug rejected by FDA
Approval for AstraZeneca and Bristol-Myers Squibb's diabetes drug dapagliflozin has been rejected by the...
Antidepressants cause three times more falls in people with dementia
Elderly people with dementia are three times more likely to have an injurious fall...